Literature DB >> 7512180

Activating mutations of the c-kit proto-oncogene in a human mast cell leukemia cell line.

Y Kanakura1, T Furitsu, T Tsujimura, J H Butterfield, L K Ashman, H Ikeda, H Kitayama, Y Kanayama, Y Matsuzawa, Y Kitamura.   

Abstract

The c-kit proto-oncogene encodes a receptor tyrosine kinase that is known to play a crucial role in mast cell growth and differentiation. In a human mast cell leukemia cell line (HMC-1), KitR was found to be constitutively phosphorylated on tyrosine, activated and associated with phosphatidylinositol 3-kinase (P13K) in the absence of autocrine production of SCF. Sequencing of c-kit cDNA revealed that c-kit genes of HMC-1 cells were composed of a normal, wild-type allele and a mutant allele with two point mutations in codon 560 and codon 816, resulting in intracellular amino acid substitutions of Gly-560 for Val and Val-816 for Asp, respectively. Murine c-kit mutants encoding Gly-559 and/or Val-814, corresponding to human Gly-560 and/or Val-816, were constructed by site-directed mutagenesis and expressed in cells of a human embryonic kidney cell line (293T). In the transfected cells, KitR (Gly-559 + Val-814) and KitR (Val-814) were strikingly phosphorylated on tyrosine and activated in the absence of SCF, whereas tyrosine phosphorylation and activation of KitR (Gly-559) or wild-type KitR was modest or little, respectively. These results suggest that constitutive activation of KitR in HMC-1 results from the activating mutations of c-kit gene, and raise the possibility that the activating mutations, particularly at codon 814 of murine c-kit or at codon 816 of human c-kit, may participate in oncogenesis of mast cells.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7512180

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  10 in total

1.  Paediatric mastocytosis.

Authors:  M C Carter; D D Metcalfe
Journal:  Arch Dis Child       Date:  2002-05       Impact factor: 3.791

2.  TPM3-ALK and TPM4-ALK oncogenes in inflammatory myofibroblastic tumors.

Authors:  B Lawrence; A Perez-Atayde; M K Hibbard; B P Rubin; P Dal Cin; J L Pinkus; G S Pinkus; S Xiao; E S Yi; C D Fletcher; J A Fletcher
Journal:  Am J Pathol       Date:  2000-08       Impact factor: 4.307

3.  Role for the adaptor protein Grb10 in the activation of Akt.

Authors:  Thomas Jahn; Petra Seipel; Susanne Urschel; Christian Peschel; Justus Duyster
Journal:  Mol Cell Biol       Date:  2002-02       Impact factor: 4.272

4.  Neoplasia driven by mutant c-KIT is mediated by intracellular, not plasma membrane, receptor signaling.

Authors:  Zhifu Xiang; Frederike Kreisel; Jennifer Cain; AnnaLynn Colson; Michael H Tomasson
Journal:  Mol Cell Biol       Date:  2006-10-23       Impact factor: 4.272

5.  A single amino acid substitution in a WW-like domain of diverse members of the PDGF receptor subfamily of tyrosine kinases causes constitutive receptor activation.

Authors:  P M Irusta; D DiMaio
Journal:  EMBO J       Date:  1998-12-01       Impact factor: 11.598

6.  KIT mutations are common in testicular seminomas.

Authors:  Kathleen Kemmer; Christopher L Corless; Jonathan A Fletcher; Laura McGreevey; Andrea Haley; Diana Griffith; Oscar W Cummings; Cecily Wait; Ajia Town; Michael C Heinrich
Journal:  Am J Pathol       Date:  2004-01       Impact factor: 4.307

7.  SETD2 and histone H3 lysine 36 methylation deficiency in advanced systemic mastocytosis.

Authors:  G Martinelli; M Mancini; C De Benedittis; M Rondoni; C Papayannidis; M Manfrini; M Meggendorfer; R Calogero; V Guadagnuolo; M C Fontana; L Bavaro; A Padella; E Zago; L Pagano; R Zanotti; L Scaffidi; G Specchia; F Albano; S Merante; C Elena; P Savini; D Gangemi; P Tosi; F Ciceri; G Poletti; L Riccioni; F Morigi; M Delledonne; T Haferlach; M Cavo; P Valent; S Soverini
Journal:  Leukemia       Date:  2017-06-16       Impact factor: 11.528

Review 8.  Preclinical human models and emerging therapeutics for advanced systemic mastocytosis.

Authors:  Michel Arock; Ghaith Wedeh; Gregor Hoermann; Siham Bibi; Cem Akin; Barbara Peter; Karoline V Gleixner; Karin Hartmann; Joseph H Butterfield; Dean D Metcalfe; Peter Valent
Journal:  Haematologica       Date:  2018-07-05       Impact factor: 9.941

9.  The phosphoinositide 3-kinase pathway in human cancer: genetic alterations and therapeutic implications.

Authors:  Alexandre Arcaro; Ana S Guerreiro
Journal:  Curr Genomics       Date:  2007-08       Impact factor: 2.236

10.  Altered trafficking of mutated growth factor receptors and their associated molecules: implication for human cancers.

Authors:  Shunsuke Kon; Nobuhide Kobayashi; Masanobu Satake
Journal:  Cell Logist       Date:  2014-03-18
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.